Early detection of multiple cancers using a blood test in healthy individuals
A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT
This study is testing a new blood test to see if it can help find different types of cancer early in healthy people aged 40 to 75 who are at risk.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12500 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Sponsor | Guangzhou Burning Rock Dx Co., Ltd. Industry-sponsored |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT05227534 on ClinicalTrials.gov |
What this trial studies
PREVENT is a multicenter interventional study that evaluates the effectiveness of the OverC multi-cancer detection blood test in asymptomatic individuals at risk for cancer. Participants aged 40 to 75 will undergo this blood test alongside standard cancer screening methods. The study aims to identify various cancer types and stages through the results of the OverC test, with approximately 12,500 participants enrolled over a 9-month period across 30 clinical sites in China. Follow-up will continue for about 5 years to monitor outcomes.
Who should consider this trial
Good fit: Ideal candidates are asymptomatic individuals aged 40 to 75 who have not undergone certain cancer screenings in the past five years.
Not a fit: Patients with existing cancer symptoms or those who have recently undergone specific cancer screenings will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of multiple cancers, improving treatment outcomes for patients.
How similar studies have performed: Other studies have shown promise in early cancer detection using blood tests, but the specific approach of the OverC test is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must be able to provide a written informed consent form * Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form * Participants must be able to provide blood samples for study tests * Participants must be between 40 and 75 years old Exclusion Criteria: * Individuals who have an acute infection or inflammation within 14 days prior to recruitment * Individuals with cancer-associated clinical symptoms or suspected of cancer * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant * Recipient of blood transfusion within 7 days prior to recruitment * Individuals who have pure ground-glass opacity * Unable to provide blood samples for the multi-cancer early detection blood test * Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests * Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment * Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment * Individuals with hemorrhagic diseases * Individuals with autoimmune diseases * Individuals who are pregnant or lactating * Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
Where this trial is running
Chengdu, Sichuan
- West China Hospital, Sichuan University — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Shangli Cai
- Email: shangli.cai@brbiotech.com
- Phone: 13811823843
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.